Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGG1 | O15527 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28392149 | 0.83 | RXRA (0.47) | OGG1KDM4EMAOBRXRARXRB | |
| SCHEMBL337714 | 0.81 | CYP3A4 (0.63) | OGG1KDM4EMAOAMAOBLMNA | |
| Ammonia Solution, Strong SCHEMBL28761898 | 0.79 | CYP3A4 (0.61) | OGG1KDM4EMAOAMAOBLMNA | |
| SCHEMBL28630633 | 0.79 | LMNA (0.67) | MAOBLMNACYP3A4KMT2AL3MBTL1 | |
| SCHEMBL10767287 | 0.79 | CYP3A4 (0.67) | LMNACYP3A4POLBPARP1 | |
| SCHEMBL8438276 | 0.78 | KMT2A (0.54) | MAOAMAOBKMT2AL3MBTL1NPC1 | |
| SCHEMBL4683517 | 0.78 | LMNA (0.42) | MAOBLMNACYP3A4KMT2APARP1 | |
| SCHEMBL3645346 | 0.78 | MAOB (0.44) | KDM4EMAOAMAOBLMNACYP3A4 | |
| SCHEMBL4273850 | 0.78 | CYP1A2 (0.46) | KDM4EMAOBLMNACYP3A4KMT2A | |
| SCHEMBL1281293 | 0.77 | LMNA (0.52) | KDM4EMAOBRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104837843-B | Imidazopyridazine derivant as GABAA receptor modulators | 辉瑞有限公司 | 2016-08-31 | — | — | CN | disclosed |
| CN-104837843-A | Imidazopyridazine derivatives as GABAA receptor modulators | PFIZER | 2015-08-12 | — | — | CN | disclosed |
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | BOUILLOT ANNE MARIE JEANNE | 2010-05-13 | — | — | US | disclosed |
| CN-1934099-A | N-piperidine derivates as CCR3 modulators | ASTRAZENECA AB (SE) | 2007-03-21 | — | — | CN | disclosed |
| CN-1780822-A | Use of derivatives of 2, 4-dihydro- 1,2,4 triazole-3-thione as inhibitors of the enzyme myeloperoxidase (MPO) | ASTRAZENECA AB (SE) | 2006-05-31 | — | — | CN | disclosed |
| EP-0783308-A1 | USE OF 9-DEOXY PROSTAGLANDIN DERIVATIVES TO TREAT GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010407-A1 | USE OF 9-DEOXY PROSTAGLANDIN DERIVATIVES TO TREAT GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | OGG1 4123/4885KDM4E 1233/4885MAOA 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.